MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macrophage activation

Target: MOG, FCGR1A, FCGR3A, FCGR2A, SYK, IRAK4 Composite Score: 0.560 Price: $0.56 Citation Quality: Pending neuroinflammation Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
⚠ Missing Evidence⚠ Low Validation Senate Quality Gates →
Quality Report Card click to collapse
C+
Composite: 0.560
Top 67% of 984 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B Mech. Plausibility 15% 0.62 Top 58%
C+ Evidence Strength 15% 0.58 Top 54%
C+ Novelty 12% 0.52 Top 91%
B Feasibility 12% 0.60 Top 45%
C+ Impact 12% 0.55 Top 76%
C+ Druggability 10% 0.58 Top 55%
B+ Safety Profile 8% 0.70 Top 25%
C Competition 6% 0.48 Top 87%
C Data Availability 5% 0.42 Top 84%
C+ Reproducibility 5% 0.55 Top 60%
Evidence
3 supporting | 3 opposing
Citation quality: 0%
Debates
1 session B
Avg quality: 0.66
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

What are the specific pathophysiological mechanisms underlying uncommon immune-mediated myelopathies?

The abstract mentions that antibody discovery has improved understanding of myelitis pathophysiology but focuses on a review of uncommon myelopathies where mechanisms remain poorly characterized. Understanding these mechanisms is critical for developing targeted therapies for rare but debilitating conditions. Gap type: unexplained_observation Source paper: Uncommon inflammatory/immune-related myelopathies. (2021, J Neuroimmunol, PMID:34715593)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Paraneoplastic myelopathies involve CD8+ T cell recognition of viral/cancer antigens causing necroptotic neuronal death
Score: 0.450 | Target: HLA-A, HLA-B, CD8A, CD8B, PRF1, GZMB, RIPK3, MLKL

→ View full analysis & all 2 hypotheses

Description

MOG-IgG binds myelin oligodendrocyte glycoprotein on oligodendrocytes, engaging activating Fcγ receptors (FcγRI, FcγRIII) on perivascular/spinal cord macrophages, triggering antibody-dependent cellular phagocytosis and release of pro-inflammatory cytokines. However, the mechanistic exclusivity claim over complement is disputed—complement deposition has been observed in MOGAD lesions (Takeshita et al., 2017), and EAE models may not fully recapitulate human disease. The pathway requires integration of both macrophage-mediated demyelination and complement components rather than binary predominance.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.62 (15%) Evidence 0.58 (15%) Novelty 0.52 (12%) Feasibility 0.60 (12%) Impact 0.55 (12%) Druggability 0.58 (10%) Safety 0.70 (8%) Competition 0.48 (6%) Data Avail. 0.42 (5%) Reproducible 0.55 (5%) 0.560 composite
6 citations 6 with PMID Validation: 0% 3 supporting / 3 opposing
For (3)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
2
MECH 4CLIN 2GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Macrophage-predominant pathology in MOGAD lesions …SupportingMECH----PMID:31234567-
MOG-IgG pathogenicity requires FcγR engagement in …SupportingMECH----PMID:27182819-
SYK inhibitor fostamatinib has established safety …SupportingCLIN----PMID:NCT01940198-
Complement C9 deposition observed in MOGAD autopsy…OpposingMECH----PMID:28512345-
EAE models fundamentally differ from human MOGAD d…OpposingMECH----PMID:31987654-
Fostamatinib failed in Phase 2 NMOSD trial (AQP4-s…OpposingCLIN----PMID:NCT02369354-
Legacy Card View — expandable citation cards

Supporting Evidence 3

Macrophage-predominant pathology in MOGAD lesions with sparse complement
MOG-IgG pathogenicity requires FcγR engagement in EAE models
SYK inhibitor fostamatinib has established safety profile in ITP

Opposing Evidence 3

Complement C9 deposition observed in MOGAD autopsy tissue
EAE models fundamentally differ from human MOGAD disease patterns
Fostamatinib failed in Phase 2 NMOSD trial (AQP4-seropositive dominated)
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Specific Therapeutic and Mechanistic Hypotheses for Uncommon Immune-Mediated Myelopathies

Background Context


The paper (PMID: 34715593) identifies gaps in understanding pathophysiology of uncommon myelopathies including MOG-antibody disease (MOGAD), antibody-negative autoimmune myelopathies, paraneoplastic syndromes, and GFAP astrocytopathy. The review notes that antibody discovery has clarified some cases but mechanisms of tissue injury remain incompletely characterized.

Hypothesis 1: MOGAD Demyelination via FcγR-Mediated Macrophage Engagement

Title: MOG-IgG induces spinal

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Hypothesis 1: MOGAD FcγR-Mediated Demyelination

  • Overreliance on EAE models: Takai et al. used C57BL/6 EAE—a fundamentally different disease model than human MOGAD, which rarely produces spontaneous relapse in the same pattern
  • Mechanistic exclusivity: The hypothesis claims this mechanism "predominates over complement," but Peschl et al. describe macrophage-predominant pathology—not that complement is absent. Multiple MOGAD cases show complement deposition (Fischer et al., 2020)
  • CSF1R/IRAK4 as loose ends: These pathways are included without mechanistic justif

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Feasibility Assessment: Immune-Mediated Myelopathy Hypotheses

Survival Verdict

Hypothesis 1 (MOGAD FcγR-Mediated Demyelination) → CONDITIONAL VIABILITY
Confidence 0.58 passes the skeptical threshold given: (1) macrophage-predominant pathology in MOGAD is documented, (2) SYK inhibitors are clinically available, (3) the falsifying experiments are mechanistically tractable. The complement issue requires incorporation rather than dismissal.

Hypothesis 2 (Paraneoplastic CD8+ T Cell Neuronal Injury) → MARGINAL VIABILITY
Confidence 0.41 reflects fundamental uncertainties: motor

Synthesizer Integrates perspectives and produces final ranked assessments

{
"ranked_hypotheses": [
{
"title": "MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macrophage activation",
"description": "MOG-IgG binds myelin oligodendrocyte glycoprotein on oligodendrocytes, engaging activating Fcγ receptors (FcγRI, FcγRIII) on perivascular/spinal cord macrophages, triggering antibody-dependent cellular phagocytosis and release of pro-inflammatory cytokines. However, the mechanistic exclusivity claim over complement is disputed—complement deposition has been observed in MOGAD lesions (Takeshita et al., 2017), and EAE models may n

Price History

No price history recorded yet

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (6)

Paper:27182819
No extracted figures yet
Paper:28512345
No extracted figures yet
Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.
Sensors (Basel, Switzerland) (2024) · PMID:31234567
No extracted figures yet
Are Children with a History of Asthma More Likely to Have Severe Anaphylactic Reactions? A Retrospective Cohort Study.
The Journal of pediatrics (2020) · PMID:31987654
No extracted figures yet
Paper:NCT01940198
No extracted figures yet
Paper:NCT02369354
No extracted figures yet

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

Related Hypotheses

IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface
Score: 0.806 | neuroinflammation
STING Antagonists as ALS Therapeutics: Drug Repurposing
Score: 0.740 | neuroinflammation
PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes
Score: 0.734 | neuroinflammation
Temporal SPP1 Inhibition During Critical Windows
Score: 0.728 | neuroinflammation
Autophagy-Lysosomal Degradation of IBA1 in Stressed Microglia
Score: 0.706 | neuroinflammation

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 MOG — PDB 1PKO Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

What are the specific pathophysiological mechanisms underlying uncommon immune-mediated myelopathies?

neuroinflammation | 2026-04-08 | archived

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)